Cargando…

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience

OBJECTIVES: The aim of the study was to evaluate the efficacy and long-term safety of tocilizumab treatment in children with systemic-onset juvenile idiopathic arthritis in a single centre. MATERIAL AND METHODS: The study was based on a retrospective analysis of a cohort of 10 patients with systemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roszkiewicz, Justyna, Orczyk, Krzysztof, Smolewska, Elżbieta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263310/ https://www.ncbi.nlm.nih.gov/pubmed/30505008 http://dx.doi.org/10.5114/reum.2018.79497

Ejemplares similares

Why and How Should We Assess the Cardiovascular Risk in Patients with Juvenile Idiopathic Arthritis? A Single-Centre Experience with Carotid Intima-Media Measurements
por: Gruca, Marta, et al.
Publicado: (2023)

The impact of single nucleotide polymorphisms in MTHFR and MTRR genes on disease activity and the presence of methotrexate treatment side effects in children with juvenile idiopathic arthritis
por: Roszkiewicz, Justyna, et al.
Publicado: (2023)

The Potential Importance of MicroRNAs as Novel Indicators How to Manage Patients with Juvenile Idiopathic Arthritis More Effectively
por: Orczyk, Krzysztof, et al.
Publicado: (2021)

A Granulocyte-Specific Protein S100A12 as a Potential Prognostic Factor Affecting Aggressiveness of Therapy in Patients with Juvenile Idiopathic Arthritis
por: Orczyk, Krzysztof, et al.
Publicado: (2018)

How Does Endothelial Permeability Affect the Development of Juvenile Idiopathic Arthritis? Vascular Endothelial Cadherin as a Promising New Tool Helpful in the Diagnostic Process
por: Orczyk, Krzysztof, et al.
Publicado: (2020)

When a patient suspected with juvenile idiopathic arthritis turns out to be diagnosed with an infectious disease – a review of Lyme arthritis in children
por: Orczyk, Krzysztof, et al.
Publicado: (2017)

Are we closer to personalized therapy in juvenile idiopathic arthritis?
por: Smolewska, Elżbieta
Publicado: (2016)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

A fresh look at angiogenesis in juvenile idiopathic arthritis
por: Świdrowska-Jaros, Joanna, et al.
Publicado: (2018)

Assessment of Cardiovascular Risk Factors in Patients with Juvenile Idiopathic Arthritis
por: Gruca, Marta, et al.
Publicado: (2023)

The effect of vitamin D3 and thyroid hormones on the capillaroscopy-confirmed microangiopathy in pediatric patients with a suspicion of systemic connective tissue disease-a single-center experience with Raynaud phenomenon
por: Kapten, Katarzyna, et al.
Publicado: (2021)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
por: Yazılıtaş, Fatma, et al.
Publicado: (2020)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Comparison of uveitis in the course of juvenile idiopathic arthritis with isolated uveitis in children – own experiences
por: Zygmunt, Agnieszka, et al.
Publicado: (2018)

Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA
por: Roszkiewicz, Justyna, et al.
Publicado: (2020)

Serum Angiogenesis Markers and Their Correlation with Ultrasound-Detected Synovitis in Juvenile Idiopathic Arthritis
por: Świdrowska, Joanna, et al.
Publicado: (2015)

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis
por: Herlin, Troels
Publicado: (2010)

The paediatric rheumatologist and orphan disease – a story without happy ending
por: Roszkiewicz, Justyna, et al.
Publicado: (2016)

Safety of the COVID-19 vaccination in children with juvenile idiopathic arthritis—A observational study from two pediatric rheumatology centres in Poland
por: Opoka-Winiarska, Violetta, et al.
Publicado: (2023)

Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
por: Zhang, Ye, et al.
Publicado: (2022)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Concentration of survivin in children with oligo- and polyarticular juvenile idiopathic arthritis (JIA): diagnostic and prognostic value—a single-center study
por: Lipinska, Joanna, et al.
Publicado: (2021)

Reactive oxygen species and serum antioxidant defense in juvenile idiopathic arthritis
por: Lipińska, Joanna, et al.
Publicado: (2014)

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
por: Sawhney, Sujata, et al.
Publicado: (2012)

Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial
por: Opoka-Winiarska, Violetta, et al.
Publicado: (2018)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
por: Marvillet, I, et al.
Publicado: (2011)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Diffuse fasciitis with eosinophilia in boys: a case-based review
por: Wosiak, Agnieszka, et al.
Publicado: (2023)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
por: Iannone, Claudia, et al.
Publicado: (2023)

Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus
por: Wang, Dongdong, et al.
Publicado: (2019)

Relationship between impaired apoptosis of lymphocytes and distribution of dendritic cells in peripheral blood and synovial fluid of children with juvenile idiopathic arthritis
por: Smolewska, Elżbieta, et al.
Publicado: (2008)

Imbalance of Th17 and T-regulatory cells in peripheral blood and synovial fluid in treatment naïve children with juvenile idiopathic arthritis
por: Szymańska-Kałuża, Joanna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9ftec4mmf9fd26kj22hjchbp0i